Viewing Study NCT04607668

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:27 PM
Ignite Modification Date: 2026-01-04 @ 4:01 PM
Study NCT ID: NCT04607668
Status: TERMINATED
Last Update Posted: 2024-11-26
First Post: 2020-10-20
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
Sponsor: G1 Therapeutics, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Colorectal Cancer Metastatic View
None Myelosuppression-Adult View
None Chemotherapeutic Toxicity View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Colorectal Cancer View
None mCRC View
None colon View
None chemotherapy-induced myelosuppression View
None chemotherapy-induced neutropenia View
None chemotherapy-induced anemia View
None CDK 4/6 inhibitor View
None trilaciclib View
None FOLFOXIRI View
None bevacizumab View
None myelosuppression View
None cyclin-dependent kinase 4/6 inhibitor View
None myelopreservation View
None rectum View
None Preserve View
None PRESERVE 1 View